- Home
- VNDA vs MMD Comparison
VNDA vs MMD Comparison
Compare VNDA & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- MMD
- Stock Information
- Founded
- VNDA 2002
- MMD 2012
- Country
- VNDA United States
- MMD United States
- Employees
- VNDA N/A
- MMD N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- MMD Investment Managers
- Sector
- VNDA Health Care
- MMD Finance
- Exchange
- VNDA Nasdaq
- MMD Nasdaq
- Market Cap
- VNDA 249.4M
- MMD 274.9M
- IPO Year
- VNDA 2006
- MMD N/A
- Fundamental
- Price
- VNDA $4.39
- MMD $15.43
- Analyst Decision
- VNDA Strong Buy
- MMD
- Analyst Count
- VNDA 2
- MMD 0
- Target Price
- VNDA $16.50
- MMD N/A
- AVG Volume (30 Days)
- VNDA 346.2K
- MMD 74.7K
- Earning Date
- VNDA 11-05-2025
- MMD 01-01-0001
- Dividend Yield
- VNDA N/A
- MMD 4.88%
- EPS Growth
- VNDA N/A
- MMD N/A
- EPS
- VNDA N/A
- MMD N/A
- Revenue
- VNDA $203,467,000.00
- MMD N/A
- Revenue This Year
- VNDA $15.45
- MMD N/A
- Revenue Next Year
- VNDA $37.82
- MMD N/A
- P/E Ratio
- VNDA N/A
- MMD N/A
- Revenue Growth
- VNDA 11.78
- MMD N/A
- 52 Week Low
- VNDA $3.81
- MMD $14.30
- 52 Week High
- VNDA $5.55
- MMD $17.67
- Technical
- Relative Strength Index (RSI)
- VNDA 42.54
- MMD 75.57
- Support Level
- VNDA $4.36
- MMD $15.25
- Resistance Level
- VNDA $4.64
- MMD $14.66
- Average True Range (ATR)
- VNDA 0.16
- MMD 0.14
- MACD
- VNDA -0.03
- MMD 0.07
- Stochastic Oscillator
- VNDA 5.36
- MMD 93.75
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.